Mink Therapeutics Inc (INKT)
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker INKT. The company focuses on discovering, developing, manufacturing, and commercializing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its lead program, agenT-797, is being evaluated in multiple clinical studies, including trials for advanced esophageal, gastric, and gastro-esophageal junction adenocarcinoma, refractory solid tumors, and moderate to severe viral acute respiratory distress syndrome. MiNK is also advancing MiNK-215 and MiNK-413, which are designed for solid tumors, inflammation, and autoimmune diseases. The company has active collaborations with Autonomous Therapeutics, ImmunoScape, and C-Further. Formerly known as AgenTus Therapeutics, it changed its name in 2021 and is headquartered in New York, New York. MiNK Therapeutics operates as a subsidiary of Agenus Inc.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-INKT
|
$8.51
|
-20.5% Downside
|
Overvalued
|
$39
|
264.3% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-4.5x
|
-4.4x
|
—
|
53.655 M
|
46.77 M
|
0.0%
|
39.2%
|
-23.9
|
—
|
50.7%
|
